Clinical Trial: A Single-Arm, Single-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined with Paclitaxel and Cisplatin/Carboplatin in Patients with Persistent Cervical Cancer After Concurrent Chemoradiotherapy (China)

China, Sept. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Arm, Single-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined with Paclitaxel and Cisplatin/Carboplatin in Patients with Persistent Cervical Cancer After Concurrent Chemoradiotherapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132217

Registration Time: 2026/09/10

Type: Interventional study

Primary Sponsor: Henan Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339044

Published by HT Digital Content Services with permission from Health Daily Digest....